Research
Hormonal
GLP-1 receptor agonists exhibit neuroprotective effects in animal models of Alzheimer's and Parkinson's disease, potentially by crossing the blood-brain barrier and reducing amyloid-beta accumulation.
Current evidence for neuroprotection from GLP-1 agonists comes primarily from animal studies, showing potential to protect against Alzheimer's and Parkinson's disease mechanisms. While promising, clinical data in humans is still limited, and these drugs are not yet approved for cognitive disorders.
LimitedQualifiesLOW confidence
Studies in mice models suggest that many of the new GLP-1 receptor agonists have the ability to cross the blood-brain barrier (75,76), making them attractive therapeutic options for the treatment of neurodegenerative central nervous system disorders.
Why this rating
Based on preclinical animal models; clinical evidence in humans is limited and preliminary.
Source
<scp>GLP</scp>‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond
Donna H. Ryan et al. · Obesity · 2015
DOI 10.1002/oby.21107
narrative_reviewCited 108×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (specifically liraglutide 3.0 mg) produce clinically significant weight loss in overweight or obese individuals through reduced appetite and energy intake, rather than increased energy expenditure.Good
- GLP-1 receptor agonists provide cardiovascular benefits, including reduced blood pressure and improved endothelial function, which may occur independently of weight loss.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →